DiaMedica Therapeutics Inc (DMAC) - Total Liabilities
Based on the latest financial reports, DiaMedica Therapeutics Inc (DMAC) has total liabilities worth $5.84 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DiaMedica Therapeutics Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how DiaMedica Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See DiaMedica Therapeutics Inc (DMAC) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
DiaMedica Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of DiaMedica Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TYC Brother Industrial Co Ltd
TW:1522
|
Taiwan | NT$27.37 Billion |
|
InPlay Oil Corp
TO:IPO
|
Canada | CA$795.00 Million |
|
Edda Wind ASA
OL:EWIND
|
Norway | Nkr395.75 Million |
|
Zhejiang Giuseppe Garment Co Ltd
SHE:002687
|
China | CN¥473.05 Million |
|
Nanjing OLO Home Furnishing
SHG:603326
|
China | CN¥744.69 Million |
|
Drugs Made In America Acquisition Corp. Units
NASDAQ:DMAAU
|
USA | $7.28 Million |
|
Polaris Media
OL:POL
|
Norway | Nkr1.93 Billion |
|
Huizhong Instrumentation Co Ltd
SHE:300371
|
China | CN¥107.14 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down DiaMedica Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DMAC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DiaMedica Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DiaMedica Therapeutics Inc (2004–2025)
The table below shows the annual total liabilities of DiaMedica Therapeutics Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.26 Million | -6.52% |
| 2024-12-31 | $5.63 Million | +81.34% |
| 2023-12-31 | $3.10 Million | +20.83% |
| 2022-12-31 | $2.57 Million | +68.17% |
| 2021-12-31 | $1.53 Million | -26.62% |
| 2020-12-31 | $2.08 Million | +44.92% |
| 2019-12-31 | $1.44 Million | +9.28% |
| 2018-12-31 | $1.31 Million | +31.01% |
| 2017-12-31 | $1.00 Million | +59.98% |
| 2016-12-31 | $626.97K | -56.82% |
| 2015-12-31 | $1.45 Million | -19.80% |
| 2014-12-31 | $1.81 Million | +18.76% |
| 2013-12-31 | $1.52 Million | -3.66% |
| 2012-12-31 | $1.58 Million | +334.06% |
| 2011-12-31 | $364.56K | -34.21% |
| 2010-12-31 | $554.10K | +180.03% |
| 2009-12-31 | $197.87K | -9.24% |
| 2008-12-31 | $218.01K | -19.96% |
| 2007-12-31 | $272.38K | +411.35% |
| 2006-12-31 | $53.27K | -5.71% |
| 2005-12-31 | $56.49K | -95.57% |
| 2004-12-31 | $1.28 Million | -- |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more